WA
Winfield Associates’s SPDR S&P Biotech ETF XBI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $1.09M | Sell |
12,117
-33,471
| -73% | -$3.01M | 0.39% | 63 |
|
|
2021
Q4 | $5.1M | Sell |
45,588
-1,936
| -4% | -$217K | 1.7% | 9 |
|
|
2021
Q3 | $5.97M | Sell |
47,524
-84
| -0.2% | -$10.6K | 2.21% | 7 |
|
|
2021
Q2 | $6.45M | Buy |
47,608
+506
| +1% | +$68.5K | 2.38% | 6 |
|
|
2021
Q1 | $6.39M | Buy |
47,102
+2,056
| +5% | +$279K | 2.61% | 6 |
|
|
2020
Q4 | $6.34M | Buy |
45,046
+6,095
| +16% | +$858K | 2.68% | 7 |
|
|
2020
Q3 | $4.34M | Buy |
38,951
+10,090
| +35% | +$1.12M | 2.07% | 9 |
|
|
2020
Q2 | $3.23M | Buy |
28,861
+450
| +2% | +$50.4K | 1.65% | 13 |
|
|
2020
Q1 | $2.2M | Sell |
28,411
-4,558
| -14% | -$353K | 1.39% | 19 |
|
|
2019
Q4 | $3.14M | Sell |
32,969
-2,369
| -7% | -$225K | 1.45% | 19 |
|
|
2019
Q3 | $2.7M | Sell |
35,338
-1,190
| -3% | -$90.8K | 1.32% | 22 |
|
|
2019
Q2 | $3.2M | Buy |
36,528
+810
| +2% | +$71K | 1.66% | 17 |
|
|
2019
Q1 | $3.23M | Buy |
35,718
+6,475
| +22% | +$586K | 1.72% | 15 |
|
|
2018
Q4 | $2.1M | Sell |
29,243
-5,550
| -16% | -$398K | 1.28% | 28 |
|
|
2018
Q3 | $3.34M | Buy |
34,793
+5,393
| +18% | +$517K | 1.65% | 17 |
|
|
2018
Q2 | $2.8M | Buy |
29,400
+5,335
| +22% | +$508K | 1.5% | 21 |
|
|
2018
Q1 | $2.11M | Buy |
24,065
+7,295
| +44% | +$640K | 1.14% | 31 |
|
|
2017
Q4 | $1.42M | Buy |
16,770
+6,775
| +68% | +$575K | 0.72% | 41 |
|
|
2017
Q3 | $865K | Buy |
9,995
+2,770
| +38% | +$240K | 0.46% | 53 |
|
|
2017
Q2 | $558K | Buy |
7,225
+4,590
| +174% | +$354K | 0.31% | 72 |
|
|
2017
Q1 | $183K | Buy |
+2,635
| New | +$183K | 0.1% | 124 |
|